An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Incyte schedules Q3 2023 financial results conference call and webcast
Positive
None.
Negative
None.
WILMINGTON, Del.--(BUSINESS WIRE)--
Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 31, 2023.
The schedule for the press release and conference call/webcast is as follows:
Q3 2023 Press Release: October 31, 2023 at 7:00 a.m. ET
Q3 2023 Conference Call: October 31, 2023 at 8:00 a.m. ET
Domestic Dial-In Number: 877-407-3042
International Dial-In Number: 201-389-0864
Conference ID Number: 13741786
If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13741786.
The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
When is Incyte's Q3 2023 financial results conference call and webcast scheduled?
The conference call and webcast are scheduled for 8:00 a.m. ET on Tuesday, October 31, 2023.
What is the schedule for the press release and conference call/webcast?
The Q3 2023 press release is scheduled for October 31, 2023 at 7:00 a.m. ET, and the conference call is scheduled for October 31, 2023 at 8:00 a.m. ET.
What are the dial-in numbers for the conference call?
The domestic dial-in number is 877-407-3042, and the international dial-in number is 201-389-0864.
What is the conference ID number for the call?
The conference ID number is 13741786.
Will there be a replay of the conference call available?
Yes, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and for international callers is 201-612-7415.
Where can I access the live webcast with slides?
The live webcast with slides can be accessed at Investor.Incyte.com.
How long will the webcast replay be available?
The webcast replay will be available for ninety days.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
